remibrutinib

FDA Drug Profile — RHAPSIDO

Drug Details

Generic Name
remibrutinib
Brand Names
RHAPSIDO
Application Number
NDA218436
Sponsor
Novartis Pharmaceuticals Corporation
NDC Codes
1
Dosage Forms
TABLET
Routes
ORAL
Active Ingredients
REMIBRUTINIB

Indications and Usage

1 INDICATIONS AND USAGE RHAPSIDO ® is indicated for the treatment of chronic spontaneous urticaria (CSU) in adult patients who remain symptomatic despite H1 antihistamine treatment. Limitations of Use: RHAPSIDO is not indicated for other forms of urticaria. RHAPSIDO ® is a kinase inhibitor indicated for the treatment of chronic spontaneous urticaria (CSU) in adult patients who remain symptomatic despite H1 antihistamine treatment. ( 1 ) Limitations of Use: Not indicated for other forms of urticaria. ( 1 )